



Acarix announces outcome of warrant exercise of series 3

Acarix AB ("Acarix" or the "Company") today announces the outcome of the exercise of warrants of series 3 issued in connection with the Company's rights issue conducted in October 2023. A total of 87,157,745 warrants were exercised, corresponding to a subscription rate of approximately 96.2 percent, for the subscription of 87,157,745 new shares. The subscription price per share was SEK 0.25. Prior to the exercise period, the Company received declarations of intent and guarantee commitments corresponding to 100 percent of the warrant issue, which was announced on August 26, and August 28, 2024. Thus, approximately SEK 0.9 million, corresponding to 3.8 percent of the outstanding warrants, will be allocated to the guarantors through a directed issue on the same terms as the warrant exercise. The board of directors therefore intends, in accordance with previously communicated guarantee agreements, to resolve on a directed share issue to the guarantors, supported by the authorization from the annual general meeting on May 14, 2024. Through the exercise of the warrants and the subsequent directed share issue to the guarantors, Acarix will receive approximately SEK 22.6 million before issuance costs.

"We are absolutely delighted by this outcome and the strong support our shareholders have shown us. The proceeds from the TO3 warrants will continue to fund our US expansion where we see great potential and we look forward to keeping you updated of our progress. I want to express my deep gratitude to all of you", says Aamir Mahmood, CEO Acarix.

Background and outcome

The exercise period for the warrants of series 3 commenced on September 11, 2024, and closed on September 25, 2024. The subscription price per share upon exercise of the warrants of series 3 was SEK 0.25. Prior to the exercise period, the Company received declarations of intent and guarantee commitments corresponding to 100 percent of the warrant issue, which was announced on August 26, and August 28, 2024.

A total of 87,157,745 warrants were exercised, corresponding to a subscription rate of approximately 96.2 percent, for the subscription of 87,157,745 new shares. Thus, approximately SEK 0.9 million, corresponding to 3.8 percent of the outstanding warrants, will be allocated to the guarantors through a directed issue on the same terms as the warrant exercise. Through the exercise of the warrants and the subsequent directed share issue to the guarantors, Acarix will receive approximately SEK 22.6 million before issuance costs.

Directed share issue



The board of directors intends, in accordance with previously communicated guarantee agreements, to resolve on a directed share issue to the guarantors, supported by the authorization from the annual general meeting on May 14, 2024.

Interim shares

Exercised warrants have been replaced with interim shares (IA) pending registration with the Swedish Companies Registration Office. The conversion of interim shares to ordinary shares is expected to occur shortly after the registration with the Swedish Companies Registration Office has been finalized.

The allocation of shares to the guarantors will take place once the directed share issue has been registered with the Swedish Companies Registration Office.

Number of shares, share capital and dilution

Through the exercise of warrants, the number of shares in Acarix will increase by 87,157,745 shares, from 973,170,178 to 1,060,327,923 shares. The share capital will increase by SEK 871,577.45, from SEK 9,731,701.78 to SEK 10,603,279.23.

Through the directed share issue to the guarantors, the number of shares will increase by an additional 3,415,857 shares to 1,063,743,780 shares. The share capital will increase by an additional SEK 34,158.57, to SEK 10,637,437.80.

For existing shareholders who did not exercise warrants of series 3, the dilution amounts to approximately 8.5 percent.

Advisers

Advokatfirman Lindahl KB is acting as legal advisor and Penser by Carnegie, Carnegie Investment Bank is acting as financial advisor in connection with the exercise of warrants of series 3.

IMPORTANT INFORMATION

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Acarix in any jurisdiction, neither from Acarix nor from someone else.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction.



This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offer of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the USA, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

For more information contact:

Jennifer Monies, phone +1 (405) 550-8144, jmonies@saxum.com

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

Attachments

[Acarix announces outcome of warrant exercise of series 3](#)